Bg pattern

DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Dalbavancina Zentiva 500 mg powder for concentrate for solution for infusion EFG

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Dalbavancina Zentiva and what is it used for
  2. What you need to know before you are given Dalbavancina Zentiva
  3. How Dalbavancina Zentiva is given
  4. Possible side effects
  5. Storage of Dalbavancina Zentiva
  6. Contents of the pack and other information

1. What is Dalbavancina Zentiva and what is it used for

Dalbavancina Zentiva contains the active substance dalbavancin, which is an antibioticof the glycopeptide group.

Antibiotics are used to treat bacterial infections and are not effective against viral infections such as flu or common cold.

It is important that you follow the instructions regarding dose, administration interval, and treatment duration as indicated by your doctor.

Do not store or reuse this medicine. If you have any leftover antibiotic after completing treatment, return it to the pharmacy for proper disposal. Do not throw away medicines via wastewater or household waste.

Dalbavancin is used to treat skin and soft tissue infections (tissue under theskin) in adults and children 3 months or older.

Dalbavancin works by killing certain bacteria that can cause serious infections. It kills bacteria by interfering with the formation of bacterial cell walls.

If you also have other bacteria that cause the infection, your doctor may decide to treat you with other antibiotics in addition to dalbavancin.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given Dalbavancina Zentiva

Do not use Dalbavancina Zentivaif you are allergicto dalbavancin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you start receiving Dalbavancina Zentiva:

  • If you have or have had kidney problems. Depending on your age and kidney function, your doctor may need to reduce your dose.
  • If you have diarrhea, or have previously had diarrhea when treated with antibiotics.
  • If you are allergicto other antibiotics such as vancomycin or teicoplanin.

Diarrhea during or after treatment

If you experience diarrhea duringor afteryour treatment, contact your doctor immediately.

Do not take any medicine to treat diarrhea without first consulting your doctor.

Infusion-related reactions

Intravenous infusion with this type of antibiotic can cause redness of the upper body, hives, itching, and/or skin rash. If you experience this type of reaction, your doctor may decide to interrupt or slow down the infusion.

Other infections

The use of antibiotics can sometimes cause the appearance of a new and different infection. If this happens, your doctor will decide what to do.

Children

Do not give this medicine to children under 3 months. The effects of using dalbavancin in children under 3 months have not been sufficiently studied.

Other medicines and Dalbavancina Zentiva

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Pregnancy and breastfeeding

Dalbavancin is not recommended during pregnancy unless clearly necessary, as it is not known what effect it could have on the fetus. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. You and your doctor will decide if you should be given dalbavancin.

It is not known whether dalbavancin passes into breast milk in humans. Ask your doctor for advice before breastfeeding your baby. You and your doctor will decide if you should be given dalbavancin. You should not breastfeed while taking dalbavancin.

Driving and using machines

Dalbavancin may cause dizziness. Be careful when driving or using machines after you have been given this medicine.

Dalbavancina Zentiva contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose; it is essentially “sodium-free”.

3. How Dalbavancina Zentiva is given

Dalbavancina Zentiva will be given to you by a doctor or nurse.

  • Adults: dalbavancin is given as a single dose of 1,500 mg or in two doses with a week's difference: 1,000 mg on day 1 and 500 mg on day 8.
  • Children and adolescents from 6 years to less than 18 years:dalbavancin is given as a single dose of 18 mg/kg (maximum 1,500 mg).
  • Young children and children from 3 months to less than 6 years:dalbavancin is given as a single dose of 22.5 mg/kg (maximum 1,500 mg).

The dose for children from 3 months to less than 18 years will be calculated by the doctor based on the child's age and weight.

You will be given dalbavancin through a drip directly into your bloodstream through a vein (intravenously) over 30 minutes.

Patients with chronic kidney problems

If you have chronic kidney problems, your doctor may decide to reduce your dose. There is not enough information to recommend the use of dalbavancin in children with chronic kidney problems.

If you are given more Dalbavancina Zentiva than you should

Tell your doctor or nurse immediately if you think you may have been given too much dalbavancin.

If you miss a dose of Dalbavancina Zentiva

Tell your doctor or nurse immediately if you are concerned that you may miss the 2nd dose.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Tell your doctor immediately if you have any of these symptoms - you may need urgent medical attention:

  • Sudden swelling of the lips, face, throat, or tongue; severe rash; itching; throat tightness; low blood pressure; difficulty swallowing and/or difficulty breathing.These may be signs of a hypersensitivity reaction and can be life-threatening. This reaction has been reported as a rare side effect.It can affect up to 1 in 1,000 people.
  • Abdominal pain (stomach)and/or watery diarrhea. The symptoms can be severe or may not go away, and the stools may contain blood or mucus. These can be signs of an intestinal infection. In this situation, you must stoptaking medicines that stop or reduce bowel movement. Intestinal infection has been reported as an uncommon side effect. It can affect up to 1 in 100 people.
  • Changes in hearing. They have been reported with a similar medicine. The frequency is unknown. It is not possible to estimate the frequency from the available data.

Other side effects that have been reported with Dalbavancina Zentiva are listed below.

Talk to your doctor, pharmacist, or nurse if you get any of the following side effects:

Common – (may affect up to 1 in 10 people):

  • Headache
  • Feeling sick (nausea)
  • Diarrhea

Uncommon – (may affect up to 1 in 100 people):

  • Vaginal infections, fungal infections, oral thrush
  • Urinary tract infections
  • Anemia (low red blood cell count), high platelet count in blood (thrombocytosis), increased count of a type of white blood cell called eosinophils (eosinophilia), low levels of other types of white blood cells (leucopenia, neutropenia)
  • Changes in other blood tests
  • Loss of appetite
  • Difficulty sleeping
  • Dizziness
  • Change in taste
  • Inflammation and swelling of superficial veins, flushing
  • Cough
  • Abdominal pain and discomfort, indigestion, constipation
  • Abnormal liver function tests
  • Increased alkaline phosphatase (an enzyme found in the body)
  • Itching, hives
  • Genital itching (women)
  • Pain, redness, or swelling at the infusion site
  • Feeling of warmth
  • Increased gamma-glutamyl transferase levels in blood (an enzyme produced by the liver and other body tissues)
  • Rash
  • Vomiting

Rare – (may affect up to 1 in 1,000 people):

  • Breathing difficulties (bronchospasm)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificarRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Dalbavancina Zentiva

Keep this medicine out of the sight and reach of children.

Do notuse this medicine after the expiry date which is stated on the vial after EXP.

The expiry date is the last day of the month stated.

The physical and chemical stability of Dalbavancina Zentiva has been demonstrated for both the reconstituted concentrate and the diluted solution for 48 hours at or below 25 °C. The total in-use stability from reconstitution to administration should not exceed 48 hours.

From a microbiological point of view, the product should be used immediately. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not exceed 24 hours between 2 and 8 °C, unless the reconstitution/dilution has been carried out under controlled and validated aseptic conditions. Do not freeze.

This medicine does not require any special storage conditions if kept in the original package.

Do not use the Dalbavancina Zentiva solution for infusion if you notice any particles or the solution is cloudy.

Dalbavancina Zentiva is for single use.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

Dalbavancina Zentiva Composition

  • The active substance is dalbavancin. Each vial of powder contains dalbavancin hydrochloride equivalent to 500 mg of dalbavancin.
  • The other ingredients are mannitol (E421), lactose monohydrate, 0.1M hydrochloric acid and/or 0.1M sodium hydroxide (only for pH adjustment).

Product Appearance and Container Content

Dalbavancina Zentiva powder for concentrate for solution for infusion is provided in a 50 ml glass vial with a grey bromobutyl stopper and sealed with an aluminium tear-off cap and green flip-off. The vial contains white or off-white to light yellow powder or compact powder.

It is available in packs containing 1 vial.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Zentiva, k.s.,

U kabelovny 130,

Prague 10 – Dolní Mecholupy,

102 37 Czech Republic

Manufacturer

SAG Manufacturing, S.L.U.

Ctra. N-I, Km 36

San Agustin de Guadalix, 28750

Madrid – Spain

or

Galenicum Health, S.L.U.

Calle Sant Gabriel, 50

08950 Esplugues de Llobregat,

Barcelona – Spain

For further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

Zentiva Spain S.L.U.

Avenida de Europa, 19, Edificio 3, Planta 1.

28224 Pozuelo de Alarcón, Madrid

Spain

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

Malta: Dalbavancin Zentiva 500 mg powder for concentrate for solution for infusion

Germany: Dalbavancin Zentiva 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

France: DALBAVANCINE ZENTIVA 500 mg, poudre pour solution à diluer pour perfusion

Italy: Dalbavancina Zentiva

Spain: Dalbavancina Zentiva 500 mg polvo para concentrado para solución para perfusión EFG

Austria: Dalbavancin Zentiva 500 mg Pulver für ein Konzentrat zur Herstellung eine Infusionslösung

Sweden: Dalbavancin Zentiva

Date of last revision of this leaflet: July 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

----------------------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Important:Consult the Summary of Product Characteristics before prescribing this medicinal product.

Dalbavancina Zentiva must be reconstituted with sterile water for injection and subsequently diluted with 50 mg/ml (5%) glucose solution for infusion.

The vials of Dalbavancina Zentiva are for single use.

Instructions for reconstitution and dilution

Aseptic technique must be used for the reconstitution and dilution of Dalbavancina Zentiva.

  1. The contents of each vial must be reconstituted by slowly adding 25 ml of water for injectable preparations.
  2. Do not shake.To avoid foam formation, gently swirl and invert the vial until the contents are completely dissolved. The reconstitution time may be up to 5 minutes.
  3. The reconstituted concentrate in the vial contains 20 mg/ml of dalbavancin.
  4. The reconstituted concentrate must be a clear, colourless to yellow solution without visible particles.
  5. The reconstituted concentrate must be diluted with a 50 mg/ml (5%) glucose solution for infusion.
  6. To dilute the reconstituted concentrate, the appropriate volume of the 20 mg/ml concentrate must be transferred from the vial to an intravenous bag or bottle containing 50 mg/ml (5%) glucose solution for infusion. For example: 25 ml of the concentrate contains 500 mg of dalbavancin.
  7. After dilution, the infusion solution must have a final concentration of 1 to 5 mg/ml of dalbavancin.
  8. The infusion solution must be a clear, colourless to yellow solution without visible particles.
  9. If particles or discoloration are identified, the solution must be discarded.

Dalbavancina Zentiva must not be mixed with other medicinal products or intravenous solutions. Solutions containing sodium chloride may cause precipitation and MUST NOT be used for reconstitution or dilution. The compatibility of the reconstituted Dalbavancina Zentiva concentrate has only been established with 50 mg/ml (5%) glucose solution for infusion.

If a common intravenous line is used to administer other medicinal products in addition to Dalbavancina Zentiva, the line must be flushed before and after each Dalbavancina Zentiva infusion with 5% glucose solution for infusion.

Use in the Paediatric Population

For paediatric patients, the dose of Dalbavancina Zentiva will vary depending on the age and weight of the child up to a maximum of 1,500 mg. Transfer the required dose of the reconstituted dalbavancin solution, according to the instructions above, based on the child's weight, from the vial to an intravenous bag or bottle containing 50 mg/ml (5%) glucose solution for infusion. The diluted solution must have a final concentration of 1 to 5 mg/ml of dalbavancin.

Table 1 below provides information to prepare an infusion solution with a final concentration of 2 mg/ml or 5 mg/ml (sufficient in most cases), to be administered via a syringe pump, to achieve a dose of 22.5 mg/kg in paediatric patients from 3 to 12 months of age with a weight of 3 to 12 kg. Alternative concentrations can be prepared, but they must have a final concentration range of 1 to 5 mg/ml of dalbavancin.

Consult Table 1 to confirm the calculations. The values shown are approximate. Note that the table does NOT include all possible calculated doses in each age group, but it can be used to estimate the approximate volume for verification of the calculation.

Table 1. Preparation of Dalbavancina Zentiva (final infusion concentration 2 mg/ml or 5 mg/ml for administration via syringe pump) in paediatric patients from 3 to 12 months (dose of 22.5 mg/kg)

Patient weight (kg)

Dose (mg) to achieve 22.5 mg/kg

Volume of reconstituted dalbavancin solution (20 mg/ml) to be withdrawn from the vial (ml)

Volume of 50 mg/ml (5%) glucose solution to be added for mixing (ml)

Final concentration of dalbavancin infusion solution

Total volume to be administered via syringe pump (ml)

3

67.5

10 ml

90 ml

2 mg/ml

33.8

4

90.0

45.0

5

112.5

56.3

6

135.0

67.5

7

157.5

78.8

8

180.0

90.0

9

202.5

20 ml

60 ml

5 mg/ml

40.5

10

225.0

45.0

11

247.5

49.5

12

270.0

54.0

Disposal

Discard any unused portion of the reconstituted solution.

Disposal of the unused medicinal product and all materials that have come into contact with it must be carried out in accordance with local regulations.

Online doctors for DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION

Discuss questions about DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Томаш Гжеловський

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
0.0 (0)
Doctor

Даниэль Чики

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance.

His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation.

Patients commonly consult Dr Daniel Cichi for:

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.
Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.
Camera Book a video appointment
€55
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (764)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION?
DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION?
The active ingredient in DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION is dalbavancin. This information helps identify medicines with the same composition but different brand names.
Who manufactures DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION?
DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION is manufactured by Zentiva K.S.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to DALBAVANCINA ZENTIVA 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION?
Other medicines with the same active substance (dalbavancin) include DALBAVANCIN ACCORD 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, DALBAVANCIN BAXTER 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, DALBAVANCIN SALA 500 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media